Fewer cancers.
Better survival.
Equity for all.

Recent changes in the last 30 days:

New regimens

• CRC ACA Metastatic - nivolumab Q2W [flat dosing]

• CRC ACA Metastatic - nivolumab Q4W [flat dosing]

• CRC ACA Metastatic - pembrolizumab Q3W [flat dosing]

• CRC ACA Metastatic - pembrolizumab Q6W [flat dosing]

• CRC Metastatic - fruquintinib

• CRC Metastatic - regorafenib 120

• CRC REC Neoadjuvant - OPRA Total Neoadjuvant Therapy

• CRC REC Neoadjuvant - PROSPECT Total Neoadjuvant Therapy

• GU URO Neoadjuvant/Adjuvant - cISplatin [split dose], gemcitabine and durvalumab

• GU URO Neoadjuvant/Adjuvant - cISplatin, gemcitabine and durvalumab

• UGI OES Advanced/Metastatic - nivolumab Q2W [flat dosing]

• UGI OES Advanced/Metastatic - nivolumab Q4W [flat dosing]

• UGI PANC Advanced - fluorouracil chemoradiation

Updated regimens

• GU GCT Advanced - EP [etoposide and cISplatin] [5-day]

• GU GCT Metastatic - BEP [bleomycin, etoposide and cISplatin] [5-day]

• GU GCT Metastatic - TIP [PACLItaxel, IFOSFamide and cISplatin]

• GU GCT Metastatic - VIP [etoposide, IFOSFamide and cISplatin]

• GU GCT Non-seminoma Adjuvant - BEP [bleomycin, etoposide and cISplatin]

• GU Penile Advanced - TIP [PACLItaxel, IFOSFamide and cISplatin] [5-day]

• GYN Ovarian germ cell tumour - BEP [bleomycin, etoposide and cISplatin]

• HN NPC Locally advanced - cARBOplatin chemoradiation followed by cARBOplatin and fluorouracil

• HN NPC Locally advanced - cISplatin [Q1W] chemoradiation

• HN NPC Locally advanced - cISplatin [Q3W] chemoradiation followed by cISplatin and fluorouracil

• HN NPC Locally advanced - gemcitabine and cISplatin followed by cISplatin chemoradiation

• HN SQCC Locally advanced - cISplatin [Q1W] post-operative chemoradiation

• HN SQCC Locally advanced - cISplatin [Q3W] post-operative chemoradiation

• HN SQCC Locally advanced - TPF [DOCEtaxel, ciSplatin and fluorouracil] followed by cARBOplatin chemoradiation

• HN SQCC Locally advanced/Definitive - cARBOplatin and fluorouracil chemoradiation

• HN SQCC Locally advanced/Definitive - CETUximab chemoradiation

• HN SQCC Locally advanced/Definitive - cISplatin [Q1W] chemoradiation

• HN SQCC Locally advanced/Definitive - cISplatin [Q3W] chemoradiation

• UGI GAST AND OES Neoadjuvant/Adjuvant - FLOT [DOCEtaxel, oxaliplatin, foliNIc acid and fluorouracil] [high dose foliNIc acid]

• UGI GAST AND OES Neoadjuvant/Adjuvant - FLOT [DOCEtaxel, oxaliplatin, foliNIc acid and fluorouracil] [low dose foliNIc acid]

• UGI GIST Metastatic - regorafenib 160

• UGI GIST Neoadjuvant/Adjuvant - imatinib

• UGI OES Definitive - cISplatin and fluorouracil chemoradiation [Herskovic]

• UGI OES Neoadjuvant - cISplatin and fluorouracil chemoradiation

• UGI PANC Locally advanced - capecitabine chemoradiation [5 day dosing]

• UGI PANC Locally advanced - capecitabine chemoradiation [continuous dosing]

Superseded regimens

• CRC Metastatic - CETUximab [Q1W]

• CRC Metastatic - regorafenib

Discontinued regimens

No recent discontinued regimens

Regimens taken offline

No regimens taken offline recently